Acceleron Pharma Inc. (NASDAQ: XLRN) announced ACE-083 Phase 1 clinical trial results in healthy volunteers at the 14th International Congress ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE